EXAS - Exact Sciences Corporation
| Previous Close | 68.87 |
| Open | 68.35 |
| Bid | 71.75 x 1300 |
| Ask | 72.90 x 800 |
| Day's Range | 67.62 - 71.99 |
| 52 Week Range | 37.36 - 81.22 |
| Volume | 903,581 |
| Avg. Volume | 2,117,109 |
| Market Cap | 8.773B |
| Beta (3Y Monthly) | 3.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.03 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 88.00 |
- CNBC Videos•14 days ago
Exact Sciences CEO on the Cologuard maker's surge in reve...
Exact Sciences CEO Kevin Conroy recaps his comapany's quarterly results with CNBC's Meg Tirrell, discussing his growth strategy, Exact Sciences' new partnership with Pfizer, and the company's flagship at-home test for colon cancer.
- Motley Fool•10 hours ago
Better Buy: EXACT Sciences Corporation vs. Illumina
Which of these two fast growers in the smarter choice for new money today?
- GuruFocus.com•2 days ago
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $11.3 million of Shares
President and CEO of Exact Sciences Corp (NASDAQ:EXAS) Kevin T Conroy sold 163,514 shares of EXAS on 11/12/2018 at an average price of $69 a share.
- ACCESSWIRE•4 days ago
Today’s Research Reports on Stocks to Watch: OPKO Health and Exact Sciences
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellar third quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable ...
Markit•8 days agoSee what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
- PR Newswire•8 days ago
Exact Sciences to participate in two November investor conferences
MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.
- Motley Fool•11 days ago
Is Exact Sciences Corporation a Buy?
It's riding high right now. But can Exact Sciences keep the momentum going?
- GlobeNewswire•12 days ago
Report: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
GuruFocus.com•15 days agoEaton Vance Worldwide Health Sciences Fund Picks Up 6 Stocks in 3rd Quarter
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed it established six new positions when it released its third-quarter portfolio. Warning! GuruFocus has detected 7 Warning Signs with COO.
Markit•15 days agoSee what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of EXAS earnings conference call or presentation 30-Oct-18 9:00pm GMT
Q3 2018 Exact Sciences Corp Earnings Call
- TheStreet.com•16 days ago
Exact Sciences Stock: Buy at What Level?
was mentioned during the "Lightning Round" on Jim Cramer's Mad Money program Wednesday night. In the daily bar chart of EXAS, below, we can see a stock chart that looks very hard to trade or even just to buy and hold. The daily On-Balance-Volume (OBV) line generally moves up from a February low to generally confirm the advance.
- Motley Fool•16 days ago
Here's What Exact Sciences Just Said About Its Future
Sales are surging, but the company is only scratching the surface of its addressable market.
- Motley Fool•17 days ago
Why Accuray Is Soaring Today
Shares jump after the company reports mixed fiscal 2019 first-quarter results.
- Benzinga•17 days ago
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 30) Gamida Cell Ltd (NASDAQ: GMDA ) NeoGenomics, Inc. (NASDAQ: ...
- ACCESSWIRE•17 days ago
Today's Research Reports on Trending Tickers: Exact Sciences and Illumina
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...
- Zacks•17 days ago
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 28.57% and 8.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•17 days ago
Exact Sciences: 3Q Earnings Snapshot
The Madison, Wisconsin-based company said it had a loss of 37 cents per share. Losses, adjusted for non-recurring costs, were 30 cents per share. The results beat Wall Street expectations. The average ...
- PR Newswire•17 days ago
Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter
- Demand accelerated from healthcare providers as more than 11,000 ordered their initial Cologuard test during the third quarter, and nearly 132,000 have ordered since the test was launched - Gross margin ...
- InvestorPlace•19 days ago
7 Rising Healthcare Stocks to Consider
The recovery in healthcare stocks started in May 2018 but faced some selling pressure in recent weeks as market volatility increased. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell by around 4.3% in the last week, and is down slightly on the year.
Markit•19 days agoSee what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
- Zacks•23 days ago
Implied Volatility Surging for Exact Sciences (EXAS) Stock Options
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
Markit•24 days agoSee what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
- PR Newswire•last month
Exact Sciences Strengthens Pipeline Capabilities with Acquisition of Biomatrica, a Leading Provider of Biological Sample Preservation Technology
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.
- Simply Wall St.•last month
Does Exact Sciences Corporation’s (NASDAQ:EXAS) Debt Level Pose A Problem?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of US$8.3b, rarely draw their attention from the investing Read More...
